Tuesday, 20 Aug 2019

You are here

The RheumNow Week in Review – Life Savers for Rheumatologists (6.29.18)

Dr. Jack Cush reviews selected news and journal reports from the past week on RheumNow.com.

  1. European Commission has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of adults with active psoriatic arthritis (PsA) with an inadequate response to DMARDs https://t.co/G6YYXSuUyQ
  2. Study of 14 EGPA pts shows mean age 12.3 yrs, All w/ Lung, upper airway (85%), skin (71%), GI tract (64%), heart (57%). CNS & renal Dz were rare. Only 31% ANCA+. Compared to adult, kids have more ENT, CV, & GI. https://t.co/v1wwrTUgsT 
  3. MPO (myeloperoxidase) Abs(MPO-ANCA, pANCA) may be associated with a wider variety - GPA, EGPA, microscopic polyangiitis, Goodpastures, PAN, glomerulonephritis, lupus, interstitial lung dz, bronchiectasis, alveolar hemorrhage, RA, IBD, autoimmune liver dz https://t.co/cWb0UeOu0h 
  4. TMP/SMX prophylaxis following rituximab in ANCA+ associated vasculitis reduces infections by 70% (HR 0.30) - 192 AAV pts with 92 infx in 49 pts (only 1 due to PJP). https://t.co/VmVDXQqlSZ 
  5. Taiwan claims analysis of #RA patients shows that despite low rates (10-20%) of influenza vaccination, those vaccinated had a significant ~35% lower rate of death and hospitalization (sepsis, bacteremia, viremia) https://t.co/Y17d66AZnC
  6. HCQ use in Lupus associated with 32% lower risk of all cause mortality at 1 yr. (a Taiwan claims data study of 2287 #SLE patients either on or off plaquenil) https://t.co/qt4nFcYCQw
  7. The risk of psoriatic arthritis in psoriasis is 23.8% according to a systematic review and metanalysis in JAAD (using CASPAR criteria). The incidence of PsA in psoriasis ranged from 0.27-2.7/100PY https://t.co/tnw41vFQe3   
  8. Study of 20,000+ patients receiving knee or hip replacements finds that, compared to OA, #RA patients have a high risk of post-op MI (HZ 3.54) and more revision surgeries (HZ 1.61)over 10 yrs https://t.co/YXH5FqHnr0 
  9. Public Citizen Pressures FDA to Pull Febuxostat   
  10. Ixekizumab Effective in Ankylosing Spondylitis 
Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

RheumNow Podcast – Antibiotics Increase RA Risk (8.16.19)

Dr. Jack Cush reports the news and important journal articles from the past week on RheumNow.com.

RheumNow Podcast – Tricked Up Lupus Criteria (8.9.19)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com, including new SLE criteria, ULT in gout and MSU reductions, IVIG in ANCA vasculitis and non-TNF biologics outperform the TNF inhibitors.

EULAR Recommendations on Large Vessel Vasculitis

Th European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) was originally published in 2009. Since then there have been new randomised clinical trials and cohort analyses leading to an update the original recommendations.

RheumNow Podcast – More Than a Spot of Tea (8.2.19)

Dr. Jack Cush reviews the journal articles and news reports from the past week on RheumNow.com: MMP-7 and Myositis-ILD; Post-surgical gout attacks; CV events and testosterone; and a Boxed warning for tofacitinib.

RheumNow Podcast – FDA Hyperactivity (7.26.19)

Dr. Jack Cush reviews the news, journal reports, and FDA releases and deliberations covered this past week on RheumNow.com